PeptiMed announced today that under a Material Transfer Agreement it
will collaborate with the National Cancer Institute's (NCI)
Nanotechnology Characterization Laboratory (NCL), located at the
Frederick National Laboratory of Cancer Research in Frederick, MD. Under
the terms of the Agreement, PeptiMed will provide the NCL with
nanocomplex consisting of its proprietary siRNA and patented
elastin-like polypeptides (ELPs), and NCL personnel will measure
material properties indicative of safety and efficacy for potential
future dosing in the clinic.
The nanocomplex materials to be provided by PeptiMed will harbor motifs
that bind to cell adhesion molecules on the surface of cancer cells and
deliver an siRNA payload that silences the oncogene, EVI1. Initially,
the NCL will assess the physical and chemical properties of the
nanocomplexes followed by their purity and sterility in cell culture
models. A second phase of testing for various modes of toxicity may be
performed in animl models.
"We are profoundly pleased to work with the NCL to further our
understanding of PeptiMed nanomaterials," stated Scott Schneider, CEO
and co-founder of PeptiMed. "We are indeed fortunate to be able to rely
on the expertise of the professionals at the NCL to get one step closer
to the clinic."
PeptiMed co-founder Dr. Jeremy Heidel added, "The NCL has a strong track
record in assisting biotech companies [as well as government and
academic institutions] with evaluation and development of novel
nanoparticle drug delivery systems. The comprehensive battery of
measurements to be performed at the NCL will provide data and analytical
methods that will help advance our nanoparticle technology toward the
The mission of PeptiMed is to discover and provide nucleotide-based
therapies and delivery systems for nucleotide-based drugs with
unprecedented potency in ameliorating late-stage cancer while avoiding
debilitating side effects, thereby improving prognosis and quality of
life for each patient. PeptiMed has patented the hELPTM
nanoparticle delivery system for nucleotides. PeptiMed plans to begin
first-in-human studies to determine maximum tolerated and efficacious
doses of the EVIRNATM/hELPTM nanocomplex by the
end of FY2015.
This press release contains positive forward-looking statements
concerning the therapeutic value of PeptiMed's EVIRNATM/hELPTM
nanocomplex. For further information please view the website www.peptimed.com
or contact Dr. Thomas Primiano, Chief Business Officer.
[ Back To NFVZone's Homepage ]